GlassScriptPhysician profile
Christopher T Bardi
NPI 1194767723
$359.87
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $87.21 · 2021: $151 · 2022: $122.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $88.19 | 2021-2022 | |
| Corium, LLC | $54.75 | 2021-2022 | |
| Glaxosmithkline, LLC. | $48.44 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $42.98 | 2021-2022 | |
| Shire North American Group INC | $27.69 | 2019 | |
| Adlon Therapeutics L.P. | $21.66 | 2021 | |
| Ironshore Pharmaceuticals INC. | $19.16 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $18.57 | 2021 | |
| Pfizer INC. | $13.11 | 2019 | |
| Neos Therapeutics, LP | $12.75 | 2022 | |
| Sanofi Pasteur INC. | $12.57 | 2022 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Bardi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.